Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

Gisina, Alisa; Kim, Yan; Yarygin, Konstantin; Lupatov, Alexey

doi:10.3390/ijms242417398

Cited by 4 publications

(3 citation statements)

References 192 publications

(256 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The investigated markers are detected in lymphohematopoietic precursor cells (CD44 and CD133), adipose tissue stem cells and brown fat cells (CD10) [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Morphological Evaluation and Immunohistochemical Analysis of the Reparative Potential of the Buccal Fat Pad

Zhidkov,

Panin,

Drobyshev

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: There are many surgical techniques for oroantral communication treatment, one of which is the buccal fat pad. Of particular interest is the high reparative potential of the buccal fat pad, which may be contributed to by the presence of mesenchymal stem cells. The purpose of this work is to evaluate the reparative potential of BFP cells using morphological and immunohistochemical examination. Materials and Methods: 30 BFP samples were provided by the Clinic of Maxillofacial and Plastic Surgery of the Russian University of Medicine (Moscow, Russia) from 28 patients. Morphological examination of 30 BFP samples was performed at the Institute of Clinical Morphology and Digital Pathology of Sechenov University. Hematoxylin–eosin, Masson trichrome staining and immunohistochemical examination were performed to detect MSCs using primary antibodies CD133, CD44 and CD10. Results: During staining with hematoxylin–eosin and Masson’s trichrome, we detected adipocytes of white adipose tissue united into lobules separated by connective tissue layers, a large number of vessels of different calibers, as well as the general capsule of BFP. The thin connective tissue layers contained neurovascular bundles. Statistical processing of the results of the IHC examination of the samples using the Mann–Whitney criterion revealed that the total number of samples in which the expression of CD44, CD10 and CD133 antigens was confirmed was statistically significantly higher than the number of samples where the expression was not detected (p < 0.05). Conclusions: During the morphological study of the BFP samples, we revealed statistically significant signs of MSCs presence (p < 0.05), including in the brown fat tissue, which proves the high reparative potential of this type of tissue and can make the BFP a choice option among other autogenous donor materials when eliminating OAC and other surgical interventions in the maxillofacial region.

show abstract

“…The investigated markers are detected in lymphohematopoietic precursor cells (CD44 and CD133), adipose tissue stem cells and brown fat cells (CD10) [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

“…The CD44 antigen is expressed as brown staining of the cell membrane of hematopoietic cells with signs of stemness [25]. The CD133 antigen is expressed as brown staining of the membrane of cells with stemness features [26]. The CD10 antigen is expressed as brown staining of the cell membrane of brown adipocyte cells [27].…”

Section: Immunohistochemical Methodsmentioning

confidence: 99%

Morphological Evaluation and Immunohistochemical Analysis of the Reparative Potential of the Buccal Fat Pad

Zhidkov,

Panin,

Drobyshev

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Along with other reasons for which CD133 has still not found its place in clinical oncology (as reviewed in ref. [ 26 ]), the difference in CD133’s immunodetection patterns when using different antibodies is of great importance [ 27 , 28 ]. This phenomenon is often explained by the putative impact of glycosylation on the CD133 epitopes.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection

Gisina,

Yarygin,

Lupatov

2024

Biology

Self Cite

View full text Add to dashboard Cite

The membrane glycoprotein CD133 (prominin-1) is widely regarded as the main molecular marker of cancer stem cells, which are the most malignant cell subpopulation within the tumor, responsible for tumor growth and metastasis. For this reason, CD133 is considered a promising prognostic biomarker and molecular target for antitumor therapy. Under normal conditions, CD133 is present on the cell membrane in glycosylated form. However, in malignancies, altered glycosylation apparently leads to changes in the functional activity of CD133 and the availability of some of its epitopes for antibodies. This review focuses on CD133’s glycosylation in human cells and its impact on the function of this glycoprotein. The association of CD133 with proliferation, differentiation, apoptosis, autophagy, epithelial–mesenchymal transition, the organization of plasma membrane protrusions and extracellular trafficking is discussed. In this review, particular attention is paid to the influence of CD133’s glycosylation on its immunodetection. A list of commercially available and custom antibodies with their characteristics is provided. The available data indicate that the development of CD133-based biomedical technologies should include an assessment of CD133’s glycosylation in each tumor type.

show abstract

Cancer stem cells: advances in knowledge and implications for cancer therapy

Chu,

Tian,

Ning

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor heterogeneity. Cancer continues to be a significant global disease burden. In the past, surgery, radiotherapy, and chemotherapy were the main cancer treatments. The technology of cancer treatments continues to develop and advance, and the emergence of targeted therapy, and immunotherapy provides more options for patients to a certain extent. However, the limitations of efficacy and treatment resistance are still inevitable. Our review begins with a brief introduction of the historical discoveries, original hypotheses, and pathways that regulate CSCs, such as WNT/β-Catenin, hedgehog, Notch, NF-κB, JAK/STAT, TGF-β, PI3K/AKT, PPAR pathway, and their crosstalk. We focus on the role of CSCs in various therapeutic outcomes and resistance, including how the treatments affect the content of CSCs and the alteration of related molecules, CSCs-mediated therapeutic resistance, and the clinical value of targeting CSCs in patients with refractory, progressed or advanced tumors. In summary, CSCs affect therapeutic efficacy, and the treatment method of targeting CSCs is still difficult to determine. Clarifying regulatory mechanisms and targeting biomarkers of CSCs is currently the mainstream idea.

show abstract

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

Cited by 4 publications

References 192 publications

Morphological Evaluation and Immunohistochemical Analysis of the Reparative Potential of the Buccal Fat Pad

Morphological Evaluation and Immunohistochemical Analysis of the Reparative Potential of the Buccal Fat Pad

The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection

Cancer stem cells: advances in knowledge and implications for cancer therapy

Contact Info

Product

Resources

About